Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. by Kolberg, Hans-Christian et al.
UCLA
UCLA Previously Published Works
Title
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to 
Trastuzumab.
Permalink
https://escholarship.org/uc/item/1z24222q
Journal
Targeted oncology, 14(6)
ISSN
1776-2596
Authors
Kolberg, Hans-Christian
Colleoni, Marco
Santi, Patricia
et al.
Publication Date
2019-12-01
DOI
10.1007/s11523-019-00675-z
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Vol.:(0123456789)
Targeted Oncology (2019) 14:647–656 
https://doi.org/10.1007/s11523-019-00675-z
REVIEW ARTICLE
Totality of Scientific Evidence in the Development of ABP 980, 
a Biosimilar to Trastuzumab
Hans‑Christian Kolberg1 · Marco Colleoni2 · Patricia Santi3 · Georgia Savva Demetriou4 · 
Miguel Angel Segui‑Palmer5 · Yasuhiro Fujiwara6 · Sara A. Hurvitz7 · Vladimir Hanes8
Published online: 16 October 2019 
© The Author(s) 2019
Abstract
ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor 
receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), 
and metastatic gastric cancer. ABP 980 is approved in the United States, European Union, and Japan for all the indications 
of trastuzumab, based on the totality of evidence (TOE) gathered by the systematic step-wise accumulation of comparative 
analytical, preclinical, and clinical (pharmacokinetics [PK], efficacy, safety and immunogenicity) data for ABP 980 and 
trastuzumab reference product (RP). As a key first step of the ABP 980 biosimilar program, comprehensive analytical char-
acterization of critical quality attributes established that ABP 980 is structurally and functionally similar to trastuzumab RP. 
Complementing these data, results of non-clinical pharmacology, toxicology, and toxicokinetic studies supported similarity 
between ABP 980 and trastuzumab RP. A randomized study in healthy subjects demonstrated clinical PK equivalence of 
ABP 980 relative to trastuzumab RP in these subjects. In the final clinical evaluation step, a randomized comparative study 
(LILAC) confirmed the lack of clinically meaningful differences between ABP 980 and trastuzumab RP in efficacy, safety, 
and immunogenicity in women with HER2-positive EBC in the neoadjuvant–adjuvant setting. Neoadjuvant EBC represented 
a sensitive homogenous population for biosimilar demonstrations, and the primary endpoint of pathologic complete response 
served as a sensitive surrogate endpoint. An important aspect of the LILAC study design is that it is the only study that 
evaluated the effect of switching from the trastuzumab RP to a trastuzumab biosimilar during the adjuvant phase. No new or 
unexpected safety signals emerged in the clinical evaluations, with the safety profile of ABP 980 consistent with that previ-
ously described for trastuzumab. Overall, the TOE data generated for ABP 980 support the conclusion that it is highly similar 
to trastuzumab RP, thus providing the scientific justification for extrapolation to all the approved indications of trastuzumab.
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1 Introduction
ABP 980 is a biosimilar of trastuzumab  (Herceptin®), a 
recombinant immunoglobulin G1 monoclonal antibody that 
targets human epidermal growth factor receptor 2 (HER2). 
Trastuzumab is approved for the treatment of HER2-overex-
pressing metastatic breast cancer (MBC), early breast cancer 
(EBC), and metastatic gastric cancer [1]. The HER family 
of transmembrane receptor tyrosine kinases is implicated in 
the regulation of several pathways involved in cell growth, 
proliferation, and survival; overexpression of HER2 results 
in activation of such cellular pathways, which ultimately 
confers cancer cells with a growth and survival advantage [2, 
3]. Upon binding to the extracellular domain of HER2 over-
expressed on cancer cells, trastuzumab mediates its effects, 
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Key Points 
Biosimilars are a new therapeutic category that has 
potential to increase access to important biologic thera-
pies while mitigating cost barriers.
Trastuzumab reference product (RP) is an integral treat-
ment component in the management of HER2-positive 
breast cancer and gastric cancer.
ABP 980, a biosimilar for trastuzumab, represents an 
alternative treatment option for all the current indications 
of trastuzumab, based on the totality of evidence sup-
porting clinical similarity in efficacy, safety, and immu-
nogenicity, which is maintained after a single switch 
from trastuzumab RP to ABP 980.
patients with HER2-positive breast cancer [11, 12]. It is also 
indicated (in combination with capecitabine or 5-fluoroura-
cil and cisplatin) for the treatment of adult patients with 
HER2-positive metastatic adenocarcinoma of the stomach 
or gastroesophageal junction who have not received prior 
anti-cancer treatment for their metastatic disease. ABP 
980 is also approved in Japan {trastuzumab (genetical 
recombination) [trastuzumab biosimilar 2]} for treatment 
of HER2-overexpressing breast cancer and unresectable 
advanced or recurrent gastric cancer [13]. Other trastuzumab 
biosimilars approved in the US, EU, and/or Japan include 
 Ogivri® (MYL-1401O; Mylan and Biocon), Trazimera™ 
(PF-05280014; Pfizer),  Herzuma® (CT-P6; Celltrion), and 
 Ontruzant® (SB3; Samsung Bioepis).
This review outlines the step-wise biosimilar develop-
ment process used to generate the totality of evidence (TOE) 
for ABP 980, which led to its approval.
1.1  Step‑Wise Development of Biosimilars 
and Approval Pathway
Unlike small-molecule generics that are chemically defined 
and identical to the originator RP, biosimilars are not identi-
cal to their RPs; this is likely due to the unavoidable minor 
structural and functional differences that arise as a result of 
the development of a unique cell line and complex manufac-
turing processes. These differences are deemed acceptable 
if they do not impact the efficacy, safety, purity, and potency 
of the biosimilar; therefore, more extensive scientific rigor 
is applied for a biosimilar than for small-molecule generics. 
Biosimilars development is focused towards establishing 
no clinically meaningful differences between the proposed 
biosimilar and the originator RP. The European Medicines 
Agency (EMA) and the US Food and Drug Administration 
(FDA) guidelines describing non-clinical and clinical con-
siderations for the development of biosimilars recommend 
a step-wise TOE approach that begins with comprehensive 
analytical characterization, which forms the foundation of 
biosimilar development. This is followed by preclinical 
assessments and clinical pharmacology (pharmacokinet-
ics [PK] and pharmacodynamics [PD]) evaluations and, 
finally, comparative clinical evaluation of efficacy, safety, 
and immunogenicity between the proposed biosimilar and 
the RP (Fig. 1) [4–10].
It is important to note that regulatory agencies require 
that a proposed biosimilar must be compared with RP that is 
locally sourced. Thus, for approval in the US, the proposed 
biosimilar must be shown to be similar to the RP approved 
in the US, and for approval in the EU, it must be shown to be 
similar to the RP approved in the European Economic Area 
[4, 9]. From a regulatory perspective, acceptability of clini-
cal data generated utilizing a foreign-sourced comparator 
is contingent upon successful establishment of a “scientific 
primarily via inhibition of receptor activation and suppres-
sion of subsequent downstream cellular effects. Secondary 
mechanisms of action (MOAs) include antibody-dependent 
cellular cytotoxicity (ADCC) and suppression of constitutive 
HER2 cleavage/shedding, although their relative contribu-
tions to the clinical efficacy and safety of trastuzumab are 
unclear [2, 3].
A biosimilar product is highly similar to a licensed bio-
logic, i.e., its reference product (RP), and shows no clinically 
meaningful differences when compared to the RP in terms 
of safety, purity, and potency [4–10]. There is increasing 
interest in biosimilars as alternatives to their originator RP 
given their potential to improve patient access to important 
biologic treatments that are safe and efficacious. Several 
biologics, including monoclonal antibodies and growth fac-
tors, are approved or in development for the treatment and 
supportive care of cancer [10]. The impending expiration of 
patents for several biologics in oncology is expected to lead 
to an increased availability of biosimilars. Given the recent 
advent of and unfamiliarity with biosimilars, their adoption 
in clinical practice may be hindered by lack of understanding 
of terminology, evolving regulatory guidance, and uncer-
tainty about how biosimilars may be prescribed and dis-
pensed, creating the need for education among stakeholders 
regarding the process of biosimilar development, including 
their abbreviated clinical testing and their appropriate use.
ABP 980 has the same amino acid sequence as trastu-
zumab and, like trastuzumab, it binds to the extracellular 
domain of HER2, resulting in suppression of receptor activa-
tion and subsequent proliferation of HER2-overexpressing 
cells. ABP 980 has been developed for the same indications, 
dosages, and route of administration as trastuzumab. It is 
approved in the European Union (EU) and United States 
(US) (Kanjinti™ [trastuzumab]) for the treatment of adult 
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bridge” [4, 9]. The scientific bridge should demonstrate that 
the foreign-sourced RP is structurally and functionally simi-
lar to the locally sourced RP using comprehensive analytical 
similarity assessments and also demonstrate PK equivalence. 
However, in acknowledgement of the challenges and costs 
associated with conducting clinical trials using RP sourced 
from multiple regions, regulatory agencies in the US and EU 
have provisions for using foreign-sourced comparators in 
clinical studies if a scientific rationale or “scientific bridge” 
is established [4, 9]. According to the Japanese regulatory 
guidelines, the use of foreign-approved RPs is acceptable 
in clinical evaluations if Japanese patients are included in 
either a comparative PK or comparative clinical efficacy 
study [14–16].
2  Analytical Characterization
For the ABP 980 studies reviewed here, both US-approved 
and EU-authorized trastuzumab RPs were used in the com-
parative assessments. Following identification of the criti-
cal quality attributes that influence PK, efficacy, safety, and 
immunogenicity, a comprehensive analytical characteriza-
tion (structural and functional) was conducted to evaluate 
these attributes using a range of complementary state-of-the-
art analytical techniques, in order to identify any potential 
structural and functional differences between ABP 980 and 
trastuzumab RP [17, 18].
For structural characterization, key product quality 
attributes assessed included primary (e.g., intact mass, 
peptide sequence, and post-translational glycosylation) and 
higher-order protein structure (e.g., secondary and tertiary), 
product-related substances and impurities (e.g., size and 
charge variants), process-related impurities, particles and 
aggregates, physicochemical product stability before and 
after reconstitution, and general properties (e.g., protein 
content and concentration) [17, 18]. Using this systematic 
approach, the similarity assessments demonstrated that ABP 
980 was highly analytically similar to trastuzumab RP, with 
minor differences that were not expected to alter biological 
activity or clinical performance.
Functionally, similarity assessments for ABP 980 and 
trastuzumab RP compared target binding, in vitro potency 
via disruption of HER2 ligand-independent cell prolifera-
tion, and effector functions (ADCC and antibody-dependent 
cellular phagocytosis [ADCP]) via their Fc binding proper-
ties. In these studies, ABP 980 and trastuzumab RP exhib-
ited similar kinetic binding properties to HER2 and showed 
similar potency and ADCC activities in experimental cell-
based systems [17, 19–21].
Trastuzumab is used clinically in combination with mul-
tiple chemotherapeutic agents; therefore, it was of interest to 
compare the relative synergies of ABP 980 and trastuzumab 
RP with docetaxel [22, 23]. In in vitro combination studies 
using gastric cancer cells, ABP 980 and trastuzumab RP 
exhibited similar synergistic activity in the presence and 
absence of docetaxel [19]. Specifically, the combination of 
docetaxel and ABP 980 in gastric cancer cells exhibited a 
robust and clinically relevant, synergistic effect [19]. Over-
all, functional assessments supported the conclusion of bio-
similarity with respect to ABP 980 and trastuzumab RP.
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Fig. 1  ABP 980 development program: stepwise “totality-of-evi-
dence” approach for demonstration of biosimilarity to trastuzumab 
RP [modified from Markus R, McBride HJ, Ramchandani M, et al. A 
review of the totality of evidence supporting the development of the 
first adalimumab biosimilar ABP 501. Adv Ther. 2019;36(8):1833–
1850]. HER2+ human epidermal growth factor receptor 2 positive, 
PD pharmacodynamics, PK pharmacokinetics, RP reference product
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3  In Vivo Pharmacology and Toxicokinetics
In non-clinical in vivo studies, the pharmacology and toxi-
cokinetic (TK) similarity of ABP 980 was compared to tras-
tuzumab RP [19, 21]. Pharmacology studies showed that 
ABP 980 and trastuzumab RP have similar dose-dependent 
antitumor activity in tumor xenograft models overexpress-
ing HER2, using either breast or gastric cancer cells. Fur-
thermore, TK assessments using a multiple-dose cynomol-
gus monkey toxicology study demonstrated similar in vivo 
exposure and dose accumulation between the ABP 980 and 
trastuzumab RP treatment groups [19]. Taken together, the 
in vivo pharmacology, toxicology, and TK studies conducted 
support the overall conclusion of similarity between ABP 
980 and trastuzumab RP.
4  Clinical Pharmacology
The PK equivalence of ABP 980 relative to trastuzumab RP 
was demonstrated in healthy male subjects [24, 25]. In a ran-
domized, single-blind, single-dose, three-arm, parallel-group 
PK study, a total of 157 subjects were randomized 1:1:1 to 
receive a single 6-mg/kg intravenous (IV) infusion of ABP 
980 (n = 50) or trastuzumab RP (FDA-licensed, n = 52; EU-
authorized, n = 55). Trastuzumab RP was acquired from 
both the EU and the US to complete the scientific bridge, 
as previously discussed. PK equivalence was considered to 
be established if the 90% confidence intervals (CIs) for the 
ratio of least square geometric means (GMs) of primary PK 
parameters of ABP 980 versus trastuzumab RP fell within 
the standard bioequivalence criteria of 0.80 and 1.25.
Mean serum concentration–time profiles were similar 
between ABP 980 and trastuzumab RP over the entire course 
of sampling [24]. The primary PK parameters area under 
the curve (AUC) from time 0 extrapolated to infinity (AUC 
inf) and the maximum observed concentration (Cmax) as well 
as the secondary PK parameter of AUC from time 0 to the 
last quantifiable concentration (AUC last) were similar across 
groups. The 90% CIs of the ratios of the GMs were fully 
contained within the prespecified bioequivalence criteria of 
0.80–1.25, confirming the PK similarity of ABP 980 and 
trastuzumab RP (both EU and US).
The frequency of treatment-emergent adverse events 
(TEAEs) of all grades, regardless of causality, was compara-
ble across the three groups [24]. The safety profiles of ABP 
980 and trastuzumab RP were similar, including headache, 
upper respiratory tract infection, chills, pyrexia, myalgia, 
nausea, epistaxis, and arthralgia; these were consistent with 
adverse events (AEs) previously described for the trastu-
zumab RP. No TEAEs or serious adverse events (SAEs) 
related to the study drug led to study discontinuation; there 
were no SAEs that resulted in death. Immunogenicity assess-
ments, conducted at baseline prior to dosing (day 1) and at 
the end of study (day 64) or upon early study discontinua-
tion, found no pre-existing antidrug antibodies (ADAs) at 
baseline; no subjects developed ADAs during the study.
5  Clinical Evaluation
Considering the demonstrated high similarity of ABP 980 to 
trastuzumab RP with respect to structure, function, and PK, 
no clinically meaningful differences between these agents in 
efficacy, safety, or immunogenicity were expected. In order 
to confirm the clinical similarity of ABP 980 to trastuzumab 
RP, a clinical study, the LILAC study, was conducted to 
compare the treatment effect of ABP 980 with trastuzumab 
RP regarding pathologic complete response (pCR) in women 
with HER2+ EBC [26].
In biosimilar clinical studies, it is critical to choose sensi-
tive patient populations and robust study endpoints in order 
to confirm there are no clinically meaningful differences 
versus the RP [7, 27]. Accordingly, in the LILAC study, 
EBC was selected as a sensitive patient population to dem-
onstrate clinical equivalence of ABP 980 versus trastuzumab 
RP. Clinical equivalence testing in EBC allows for a careful 
and thorough biosimilarity assessment. In contrast, MBC 
can be considered a less sensitive and less homogenous 
population since prior treatment, line of therapy, disease 
burden and comorbidities, and risk of secondary cancers 
may potentially confound the results [27, 28]. Moreover, the 
metastatic setting does not allow comprehensive immuno-
genicity characterization, owing to the lack of a treatment-
free follow-up phase and the immunosuppressive effects of 
common treatment modalities, such as chemotherapy and 
radiation [28, 29].
The pCR of both the breast tissue and axillary lymph 
nodes was chosen as a sensitive endpoint in the LILAC trial 
since it has been validated to be clinically meaningful in 
the neoadjuvant EBC setting. FDA guidelines indicate that 
pCR in the neoadjuvant setting and in patients with operable 
breast cancer is the preferred primary endpoint to support 
accelerated drug approval [27]. This recommendation was 
supported by results of a meta-analysis of 12 randomized, 
controlled trials in neoadjuvant EBC, which showed that 
patients who achieved a pCR had a more favorable long-term 
survival outcome in terms of event-free survival, although 
the analysis could not establish a trial-level correlation 
between pCR and long-term outcome [30]. While long-term 
outcome, e.g., overall survival, as the primary endpoint is 
regarded as the gold standard in oncology clinical trials for 
innovator molecules, it is not considered appropriate for bio-
similar trials since it might be confounded by several fac-
tors, such as tumor burden, disease status, and previous and 
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subsequent lines of therapy. The use of objective response 
rate (ORR) is not preferred since it does not correlate reli-
ably with long-term efficacy outcomes [28, 29].
Taken together, demonstration of clinical similarity 
between the trastuzumab RP and its biosimilar in the neo-
adjuvant–adjuvant setting using pCR as the primary end-
point is preferred. This also represents a more appropriate 
approach for extrapolation to other indications, such as 
metastatic disease [29]. Therefore, the LILAC study was 
conducted in the more homogeneous neoadjuvant setting 
using a sensitive population and endpoint, making this an 
ideal study design for evaluating a biosimilar for use in 
breast cancer.
The LILAC study was a randomized, multicenter, dou-
ble-blind, active-controlled, two-phase, equivalence trial 
conducted in both the neoadjuvant and adjuvant settings, 
with a single-switch transition phase design in the adjuvant 
phase [26]. Eligible patients were randomized to one of three 
treatment arms: ABP 980, trastuzumab RP, or neoadjuvant 
trastuzumab RP followed by adjuvant ABP 980. Prior to 
randomization, patients received 12-week run-in chemo-
therapy consisting of epirubicin plus cyclophosphamide 
every 3 weeks for four cycles. Patients then received ABP 
980 or trastuzumab RP, at a loading dose of 8 mg/kg plus 
paclitaxel 175 mg/m2 in a 90-min IV infusion, followed by 
three cycles of 6 mg/kg IV ABP 980 or trastuzumab RP plus 
paclitaxel 175 mg/m2 every 3 weeks in 30-min IV infusions 
(or 80 mg/m2 paclitaxel once per week for 12 cycles if that 
was the local standard of care) [26]. Surgery was performed 
3–7 weeks after the last dose of neoadjuvant therapy. Dur-
ing the adjuvant treatment phase, patients either continued 
ABP 980 or trastuzumab RP (6 mg/kg), or switched from 
trastuzumab RP to ABP 980 every 3 weeks for up to 1 year 
after the first dose in the study.
The co-primary efficacy endpoints of the LILAC trial 
were risk difference (ABP 980 minus trastuzumab RP) and 
risk ratio (RR) (ABP 980 vs trastuzumab RP) of pCR, which 
was defined as the absence of invasive tumor cells in the 
breast tissue and in axillary lymph nodes regardless of ductal 
carcinoma in situ. This was the first multicenter neoadjuvant 
breast cancer study that incorporated an independent central 
pathology review of pCR (sensitivity analysis) in addition 
to the local pathology review (primary analysis); both were 
conducted in all patients who were randomized and received 
neoadjuvant treatment followed by surgery.
A total of 827 patients were enrolled in the trial; 725 
patients were randomized to receive ABP 980 (n = 364) 
or trastuzumab RP (n = 361) [26]. By protocol-defined 
criteria, similarity between ABP 980 and trastuzumab RP 
was established if the two-sided 90% CI for the risk dif-
ference between the ABP 980 and trastuzumab RP groups 
was within the statistical equivalence margins of − 13% and 
13%. If the risk difference was successful, similarity was 
then tested by the RR of pCR by comparing the two-sided 
90% CI between the ABP 980 and trastuzumab groups, with 
statistical margins of 0.759 and 1.318.
The primary analysis (local pathology review) found 
that a higher proportion of patients treated with ABP 980 
achieved pCR compared to those treated with trastuzumab 
RP (48% [95% CI 43–53] vs 41% [95% CI 35–46]), with 
a risk difference of 7.3% (90% CI 1.2–13.4) and an RR of 
1.188 (90% CI 1.033–1.366). It was concluded that the non-
inferiority for the primary endpoint was met; however, non-
superiority could not be excluded since the upper bounds of 
the 90% CIs for RR and risk difference exceeded the prede-
fined equivalence margins (Fig. 2) [26]. However, sensitivity 
analyses from central laboratory review confirmed clinical 
similarity of ABP 980 and trastuzumab RP in terms of pCR 
(48% vs 42%; risk difference 5.8% [90% CI − 0.5 to 12.0]; 
RR 1.142 [90% CI 0.993–1.312]) (Fig. 2) [26].
The safety analysis (including both neoadjuvant and adju-
vant phases) found that the overall incidences of AEs, events 
of interest (EOIs), and SAEs were similar between the two 
treatment groups during both the neoadjuvant and adjuvant 
phases [26]. The AE profile was consistent with the histori-
cal safety profile of trastuzumab, with no emergence of new 
safety signals during the neoadjuvant or adjuvant phases, 
or with switching (Table 1) [26]. During the neoadjuvant 
phase that included combination of investigational prod-
uct (IP) plus chemotherapy, infusion reaction was the most 
common EOI in both groups; while the most common EOIs 
during the adjuvant phase were infections and infestations, 
neutropenia, and infusion reactions. Not surprisingly, the 
incidence of AEs was higher in the neoadjuvant phase that 
was preceded by run-in chemotherapy and comprised of IP 
plus chemotherapy (paclitaxel).
Cardiac toxicity was an event of particular interest, 
given the accumulated evidence indicating increased risk 
of cardiac toxicity with trastuzumab treatment that may be 
attributable to previous anthracycline exposure [26]. Median 
left ventricular ejection fraction (LVEF) values did not 
change in any treatment group over the course of the study. 
For any time during the study, LVEF declines of ≥ 10% 
and < 50% occurred in 2.8% (ABP 980) to 3.5% (trastuzumab 
RP/ABP 980) of patients (Table 2) [26]. The frequency of 
cardiac disorders was low throughout the study, and none 
resulted in discontinuation of IP. Only seven patients expe-
rienced cardiac failure (all grade 1–2) in the neoadjuvant 
phase, and four patients experienced this in the adjuvant 
phase (one grade 3). Moreover, all 11 patients received the 
planned doses of IPs, which suggests resolution or no wors-
ening of cardiac failure. Only one of the 11 patients with 
a cardiac failure AE also had clinically significant LVEF 
findings, which suggests very low cardiac toxicity in this 
study. While long-term follow-up (median 3.6 years) in a 
study with trastuzumab RP has shown that the incidence of 
652 H.-C. Kolberg et al.
congestive heart failure and left ventricle dysfunction remain 
low with trastuzumab treatment, because there is evidence 
of a possible delayed manifestation of cardiac events with 
anthracycline, long-term follow-up is still required [31]. In 
this regard, the similar incidence of events during therapy 
with ABP 980 and trastuzumab RP is reassuring.
Notably, the safety outcomes following single switch 
from trastuzumab RP to ABP 980 were similar in terms of 
incidences of AEs and SAEs or rate of discontinuation due 
to an AE; common AEs experienced by ≥ 5% of patients 
were radiation skin injury, neutropenia, arthralgia, asthenia, 
and anemia [26]. Also, switching from trastuzumab RP to 
ABP 980 was not associated with an increase in incidence 
of cardiotoxicity. It should also be noted that cardiac toxicity 
frequencies were comparable with those previously reported 
in the literature for trastuzumab [32].
Immunogenicity was similar in patients who received 
ABP 980 and those who received trastuzumab RP. A total 
of eight patients developed ADAs at any time during the 
entire course of the study: two each in the ABP 980 and 
trastuzumab RP groups, and four in the switch group [23]. 
No patients tested positive for neutralizing antibodies.
Fig. 2  Comparative clini-
cal study results of ABP 
980 vs trastuzumab RP in 
HER2 + EBC: total pCR [26]. 
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6  Extrapolation
Finally, it is important to understand the concept of extrapo-
lation with respect to the development and approval of bio-
similars. This concept is unique to biosimilars and reduces 
or eliminates the need for clinical studies in multiple indi-
cations. Extrapolation is based on the TOE and requires 
adequate scientific justification, which includes comprehen-
sive studies designed to evaluate MOA as well as structural, 
functional, non-clinical, PK, and clinical similarity between 
the biosimilar and the RP, as have been conducted for ABP 
980. Based on this, approval for use for ABP 980 was sought 
and received in all indications for which the trastuzumab 
RP is approved, without having to perform clinical trials in 
different disease settings and patient populations, thus ena-
bling an accelerated clinical trial program. A shared MOA 
is key for the approval of biosimilars across different indi-
cations. For example, in HER2-positive breast cancer, the 
results of biosimilar clinical testing performed in the adju-
vant or neoadjuvant setting may be used for extrapolation to 
MBC or HER2-positive metastatic gastric cancer. It must be 
emphasized that the scientific justification for extrapolation 
is based on the historical knowledge and understanding of 
the originator RP regarding any potential differences in PK, 
MOA/efficacy, safety or immunogenicity across its approved 
indications predicated on the conclusion of biosimilarity of 
the biosimilar candidate.
In the case of trastuzumab, the primary MOA, inhibi-
tion of ligand-independent HER2-mediated proliferation, 
is the same across all its approved indications. Addition-
ally, the secondary MOA, ADCC, is also conserved. There 
are no differences in PK, safety, or immunogenicity across 
the approved indications of trastuzumab that would prevent 
Table 1  Comparative clinical study (LILAC trial) results of ABP 980 vs trastuzumab RP in HER2 + EBC: all grades of treatment-emergent 
adverse events
EBC early breast cancer, HER2+ human epidermal growth factor receptor 2 positive, RP reference product
Neoadjuvant phase Adjuvant phase
ABP 980 (n = 364) Trastuzumab 
RP (n = 361)
ABP 980 (n = 349) Trastuzumab 
RP (n = 171)
Switched from adjuvant trastu-
zumab RP to ABP 980 (n = 171)
Neutropenia 53 (14.6%) 45 (12.5%) 25 (7.2%) 10 (5.8%) 6 (3.5%)
Arthralgia 63 (17.3%) 55 (15.2%) 20 (5.7%) 9 (5.3%) 9 (5.3%)
Asthenia 54 (14.8%) 59 (16.3%) 18 (5.2%) 7 (4.1%) 10 (5.8%)
Anemia 40 (11.0%) 38 (10.5%) 17 (4.9%) 7 (4.1%) 10 (5.8%)
Neuropathy peripheral 51 (14.0%) 43 (11.9%) 8 (2.3%) 3 (1.8%) 2 (1.2%)
Adverse events of interest
 Infusion reactions 80 (22.0%) 68 (18.8%) 28 (8.0%) 14 (8.2%) 20 (11.7%)
 Neutropenia 69 (19.0%) 57 (15.8%) 38 (10.9%) 16 (9.4%) 13 (7.6%)
 Infections and infestations 51 (14.0%) 55 (15.2%) 54 (15.5%) 17 (9.9%) 23 (13.5%)
 Hypersensitivity 24 (6.6%) 19 (5.3%) 11 (3.2%) 7 (4.1%) 8 (4.7%)
 Cardiac failure 6 (1.6%) 1 (0.3%) 2 (0.6%) 1 (0.6%) 1 (0.6%)
 Pulmonary toxicity 1 (0.3%) 1 (0.3%) 4 (1.1%) 2 (1.2%) 1 (0.6%)
Table 2  Patients experiencing LVEF decline by ≥ 10% and to below 50%
Percentages were calculated as n/N1 × 100
IP investigational product, LVEF left ventricular ejection fraction, n number of patients experiencing LVEF decline by ≥ 10% and to below 50%, 
N1 number of patients with data available at a given assessment, RP reference product
a Results from unscheduled visits are included in the overall summary
b End of study visits were scheduled 30 days after last IP, or 1 year from first IP for patients who withdraw early
ABP 980 (N = 364)
n/N1 (%)
Trastuzumab RP (N = 190)
n/N1 (%)
Trastuzumab 
RP/ABP 980 
(N = 171)
n/N1 (%)
Any time during  studya 10/359 (2.8) 6/184 (3.3) 6/171 (3.5)
End of  studyb 9/336 (2.7) 3/168 (1.8) 5/160 (3.1)
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extrapolation to unstudied indications; thus, we conclude 
that ABP 980 should have the same clinical performance 
across all approved indications of the RP.
7  Discussion
The TOE generated for ABP 980 from analytical, functional, 
non-clinical, PK, and clinical studies shows that ABP 980 is 
highly similar to trastuzumab RP. The results of the LILAC 
study demonstrated that there are no clinically meaningful 
differences between ABP 980 and trastuzumab RP with 
respect to efficacy (based on sensitivity analysis), safety, and 
immunogenicity. Importantly, no new or unexpected safety 
signals emerged throughout the study, with the safety profile 
consistent with that previously described for trastuzumab.
7.1  Clinical Evidence from Other Trastuzumab 
Biosimilars
Four other biosimilars (CT-P6, MYL-1401O, SB3, and 
PF-05280014) have been approved by the FDA and EMA 
and have been shown to be similar to trastuzumab RP in 
confirmatory clinical studies (Table 3) [26, 33–38]. While 
all four biosimilars were evaluated with the recommended 
equivalence trial design, the patient population and primary 
endpoints in these studies differed from those used in the 
ABP 980 studies. In these five trials, anthracycline/taxane-
based chemotherapy was used in the neoadjuvant setting 
and taxane-based chemotherapy in the metastatic setting; no 
significant differences between the biosimilar trastuzumab 
and the trastuzumab RP were reported. The trials evaluat-
ing MYL-1401O, PF-05280014, and CT-P6 were conducted 
in HER2-overexpressing MBC; the primary endpoint in all 
three trials was ORR (the prespecified equivalence margin 
was ± 15%) [33, 35, 37]. As discussed earlier, MBC is a less 
sensitive and less homogenous population to demonstrate 
clinical equivalence of a biosimilar trastuzumab, and ORR 
is not the preferred primary endpoint since it is associated 
with a larger uncertainty in long-term efficacy outcomes. 
On the other hand, pCR is a direct and objective measure 
of antitumor activity that may be a potential surrogate for 
disease-free survival and overall survival in patients with 
HER2 + EBC treated with neoadjuvant chemotherapy and 
trastuzumab [39], and therefore, is considered sensitive for 
use in evaluating potential differences between trastuzumab 
biosimilar and RP. For these reasons, PF-05280014, and 
CT-P6 were subsequently evaluated in EBC, using pCR as 
the primary endpoint [34, 38]. The SB3 equivalence trial 
was conducted in the sensitive neoadjuvant EBC patient 
population using pCR as the primary endpoint; however, 
the SB3 trial evaluated pCR in breast only and did not evalu-
ate lymph node or document ductal carcinoma in situ status 
[36]. Equivalence was declared in the SB3 trial if the 95% CI 
of the RR was within 0.785–1.546 or the 95% CI of the dif-
ference was within the lower and upper equivalence margin 
of ± 13% [36]. In the context of these data, it must be noted 
that the LILAC study was designed to evaluate equivalence 
in EBC and comprehensively assessed total pCR in both 
breast tissue and axillary lymph nodes, with an equivalence 
margin of ± 13%, which provides confidence in the demon-
strated similarity between ABP 980 and the trastuzumab 
RP [26]. Moreover, the unique study design of the LILAC 
trial in terms of clinical assessments in both the neoadjuvant 
and adjuvant settings, as well as after switching from trastu-
zumab RP to ABP 980, allowed demonstration that ABP 980 
may be used in each of these settings, which are of particular 
relevance for clinical practice. Taken together, ABP 980 has 
shown no significant differences compared to its RP in terms 
of efficacy, safety, and immunogenicity, thus, supporting its 
safe and effective use in place of trastuzumab RP, in all the 
approved indications of trastuzumab, i.e., EBC, MBC, and 
metastatic gastric cancer [40].
7.2  Other Considerations
It is thought that biosimilars may provide better over-
all value by offering additional treatment options. A few 
Table 3  Comparison of trastuzumab biosimilars
EBC early breast cancer, MBC metastatic breast cancer, ORR overall response rate, pCR pathologic complete response
Trastuzumab biosimilars Clinical trial
Patient population Primary endpoint
ABP 980 (Kanjinti™; trastuzumab-anns) [26] Neoadjuvant and adjuvant EBC pCR
CT-P6  (Herzuma®; trastuzumab-pkrb) [33, 34] MBC
Neoadjuvant EBC
ORR
ORR
MYL-1401O  (Ogivri®; trastuzumab-dkst) [35] MBC ORR
SB3  (Ontruzant®; trastuzumab-pkrb) [36] Neoadjuvant EBC pCR
PF-05280014 (Trazimera™; trastuzumab-qyyp) [37, 38] MBC
Neoadjuvant EBC
ORR
pCR
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considerations that would help realize the value of biosimi-
lars include quality, sustainability, and reliability of sup-
ply without disruptions or shortages [41]. Given the grave 
impact of oncology drug shortages, including increased 
burden of time to deal with the shortage and potentially 
increased drug costs and, in some cases, elevated risk of 
medication errors, a reliable supply of high-quality bio-
similars is critical for pharmacy operations and delivery of 
patient care [42].
At this time, it is not known whether biosimilars will 
provide any cost savings in the US similar to what has been 
observed in Europe and other global regions [43]. However, 
it is expected that the expanded treatment choices provided 
by the availability of biosimilars may favorably impact the 
overall value-based delivery of care. Moreover, biosimilars 
might afford patients reduced out-of-pocket costs that might 
encourage medication adherence [41].
8  Conclusions
The TOE of ABP 980 supported the scientific justification 
for extrapolation across all approved indications of trastu-
zumab RP. The current data allow the use of ABP 980 as a 
biosimilar to trastuzumab RP, thus, providing an additional 
treatment option for patients with breast and gastric cancers.
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